CJC-1295

This is the most consequential thing to understand about this listing, and almost nobody selling it states it.

CJC-1295 is a tetrasubstituted analogue of GRF(1-29) carrying a Drug Affinity Complex: a maleimidopropionamide group on an added lysine, which forms a covalent bond with circulating albumin. That group is not an accessory. It is the defining feature of the molecule and the reason the compound carries the name it does.

Remove it and the result is not a shorter-acting CJC-1295. It is a separate compound properly designated Modified GRF (1-29), also written mod GRF (1-29) or tetrasubstituted GRF(1-29): the same four backbone substitutions, no linker, a different molecular formula and a mass roughly 280 daltons lighter. The market began calling it "CJC-1295 without DAC" and the designation stuck. We use it in the option selector because that is what people search for, and we state here what the compound actually is.

How to verify which compound you have

Registry numbers cannot be relied upon to distinguish these two products across suppliers; both are widely listed under a single CAS number. Our own certificates illustrate the problem: the identity field on the non-DAC certificate reads simply "CJC-1295," which is the trade designation rather than the compound's proper name.

The mass settles it. Reconstruct the molecular weight from the charge series on the certificate for your lot. The DAC compound lands near 3647; Modified GRF (1-29) lands near 3368. A 280 dalton gap is unmistakable on any competent trace, and it is the check to run before anything else.

02

Both options share four substitutions to the GRF(1-29) backbone: D-alanine at position 2, glutamine at 8, alanine at 15 and leucine at 27. Between them these resist dipeptidyl peptidase-4 cleavage, deamidation and oxidation, which are the liabilities of the native sequence.

Reported clearance separates them by roughly three orders of magnitude. Modified GRF (1-29) is cleared on the order of thirty minutes. With the DAC bound to albumin, reported duration extends into days.

That difference is mechanistic rather than one of convenience, and it should determine which option a protocol requires. GHRH signalling is physiologically pulsatile. A compound cleared in half an hour produces a discrete pulse. A compound tethered to albumin across days produces continuous receptor occupancy, which is a different stimulus pattern that no model of endogenous GHRH signalling will reproduce. A design depending on pulsatility will be confounded by the DAC option; a design requiring sustained occupancy cannot be served by the non-DAC option.

03

Each option is tested and released separately and carries its own certificate. Both are set out below: the interactive verification record, the certificate document, and the same information reproduced as text on this page. The record does not depend on the embeds loading.

Option A - with DAC

Certificate of analysis - lot K68WPF, with DAC

Lot record - with DAC

K68WPF

Results, lot K68WPF

Option B - without DAC, Modified GRF (1-29)

Certificate of analysis - lot J3SPEC, without DAC

Lot record - without DAC

J3SPEC

Results, lot J3SPEC

Purity and content figures above are specific to lots K68WPF and J3SPEC and are not specifications carried across other lots. Each lot is tested individually and reports its own results. The certificate supplied with your unit records the results for that lot.

04

Option A - with DAC

Option B - without DAC

05

Panels differ between products and between lots. The scope below applies to both current lots. Nothing is claimed unless it appears on the certificate for the lot supplied.

The last entry matters on the DAC option specifically. The maleimide group is the reactive handle that makes albumin conjugation possible, and it is also the most fragile part of the molecule. Its integrity is not quantified as a separate parameter on this certificate. Where a parameter is material to intended laboratory work, purchasers should verify it independently or source material released against that specification.

06

Preparation conditions are the responsibility of the receiving laboratory. Verum provides no protocol, no preparation instruction, and no guidance on use.

07

The entry below is listed for bibliographic purposes and is indexed by the experimental system used. The description states what the study measured, not what it concluded. Studies conducted in human participants are excluded. Note also that the published record concerns the DAC compound; work on it should not be assumed to transfer to the non-DAC option, which has very little literature of its own. Verum has no involvement in this work and makes no representation as to its applicability.

Work conducted in animals does not establish an effect in any other system. Nothing in the above is offered as a representation about this material.

08

09

By placing an order you confirm each of the following:

Confirmation is recorded at checkout against your order. Verum reserves the right to decline or cancel any order.

10

Orders placed before the daily cutoff are dispatched the same day from our United States warehouse. Domestic orders typically arrive within two business days. A tracking reference is issued by email once the consignment leaves the facility. Each unit carries a scannable code linking to the certificate for its own lot.

Not for human or veterinary use. Not for use in diagnostic or therapeutic procedures. This product is a laboratory reagent. Nothing on this page constitutes medical advice, a recommendation for personal use, or a representation that this material is safe or effective for any purpose. No statement here has been evaluated by the U.S. Food and Drug Administration.